306 related articles for article (PubMed ID: 17298959)
1. Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
Ayantunde AA; Parsons SL
Ann Oncol; 2007 May; 18(5):945-9. PubMed ID: 17298959
[TBL] [Abstract][Full Text] [Related]
2. Malignant ascites: demographics, therapeutic efficacy and predictors of survival.
Mackey JR; Venner PM
Can J Oncol; 1996 Nov; 6(2):474-80. PubMed ID: 12056099
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.
Jordan K; Luetkens T; Gog C; Killing B; Arnold D; Hinke A; Stahl M; Freier W; Rüssel J; Atanackovic D; Hegewisch-Becker S
Eur J Cancer; 2016 Aug; 63():127-34. PubMed ID: 27314448
[TBL] [Abstract][Full Text] [Related]
4. Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.
DeWitt J; Yu M; Al-Haddad MA; Sherman S; McHenry L; Leblanc JK
Gastrointest Endosc; 2010 Feb; 71(2):260-5. PubMed ID: 19922924
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy.
Nagata Y; Kato K; Miyamoto T; Hirano H; Shoji H; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Matsushita H; Nagashima K; Saruta M; Boku N
Support Care Cancer; 2020 Dec; 28(12):5861-5869. PubMed ID: 32253601
[TBL] [Abstract][Full Text] [Related]
6. [Pathogenesis and management of refractory malignant ascites].
Saâda E; Follana P; Peyrade F; Mari V; François E
Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
[TBL] [Abstract][Full Text] [Related]
8. [Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].
Gamblin V; Da Silva A; Villet S; El Hajbi F
Bull Cancer; 2015 Nov; 102(11):940-5. PubMed ID: 26477275
[TBL] [Abstract][Full Text] [Related]
9. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
Easson AM; Bezjak A; Ross S; Wright JG
Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
[TBL] [Abstract][Full Text] [Related]
10. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
Wimberger P; Gilet H; Gonschior AK; Heiss MM; Moehler M; Oskay-Oezcelik G; Al-Batran SE; Schmalfeldt B; Schmittel A; Schulze E; Parsons SL
Ann Oncol; 2012 Aug; 23(8):1979-1985. PubMed ID: 22734013
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
12. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites.
Quintero E; Ginés P; Arroyo V; Rimola A; Bory F; Planas R; Viver J; Cabrera J; Rodés J
Lancet; 1985 Mar; 1(8429):611-2. PubMed ID: 2857949
[TBL] [Abstract][Full Text] [Related]
13. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis.
Solbach P; Höner Zu Siederdissen C; Taubert R; Ziegert S; Port K; Schneider A; Hueper K; Manns MP; Wedemeyer H; Jaeckel E
Eur J Gastroenterol Hepatol; 2017 May; 29(5):539-546. PubMed ID: 28350743
[TBL] [Abstract][Full Text] [Related]
14. Is Low Volume Drainage of Ascites Associated With Improved Survival in Digestive System Cancer Patients With Malignant Ascites?-A Retrospective Cohort Study.
Hoshino S; Takagi Y; Fukagawa T; Sano K; Seki N; Hashiguchi Y; Aruga E
J Palliat Care; 2023 Oct; 38(4):473-480. PubMed ID: 37093798
[No Abstract] [Full Text] [Related]
15. Targeting diuretic use for malignant ascites--two case reports highlighting the value of the serum-ascites albumin gradient in a palliative setting.
Husbands EL
J Pain Symptom Manage; 2010 Feb; 39(2):e7-9. PubMed ID: 20152583
[No Abstract] [Full Text] [Related]
16. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.
Fang N; Zhang HQ; He B; Xie M; Lu S; Wan YY; Wang NR
Tumour Biol; 2014 Apr; 35(4):3261-8. PubMed ID: 24282088
[TBL] [Abstract][Full Text] [Related]
17. Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study.
Solà R; Vila MC; Andreu M; Oliver MI; Coll S; Gana J; Ledesma S; Ginès P; Jiménez W; Arroyo V
J Hepatol; 1994 Feb; 20(2):282-8. PubMed ID: 7516361
[TBL] [Abstract][Full Text] [Related]
18. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract][Full Text] [Related]
19. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
[TBL] [Abstract][Full Text] [Related]
20. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
